Orriols Ludivine, Luxcey Audrey, Contrand Benjamin, Bénard-Laribière Anne, Pariente Antoine, Gadegbeku Blandine, Lagarde Emmanuel
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team IETO, UMR 1219, F-33000 Bordeaux, France.
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team IETO, UMR 1219, F-33000 Bordeaux, France.
Accid Anal Prev. 2017 Sep;106:115-121. doi: 10.1016/j.aap.2017.05.030. Epub 2017 Jun 8.
H1 antihistamines differ from each other by their ability to cross the blood-brain barrier. The resulting sedating effect can be sought in therapy but may be a driving hazard. The aim of this study was to estimate the impact of sedating H1-antihistamines on the risk of road traffic crash, with a particular focus on hydroxyzine which is also indicated as an anxiolytic in France.
The study consisted in extracting and matching data from three French nationwide databases: the national healthcare insurance database, police reports and the police national database of injurious crashes. All sedating H1-antihistamines, including hydroxyzine, were considered in the study. A case-control analysis, in which responsible drivers were cases and non-responsible were controls was performed. A case-crossover analysis, comparing for the same subject exposure during a period immediately before the crash with exposure during an earlier period, was also conducted.
The extraction and matching procedures over the July 2005-December 2011 period led to the inclusion of 142,771 drivers involved in an injurious road traffic crash. The responsibility study found an increased risk of being responsible for an injurious road traffic crash in hydroxyzine users who were registered with a long-term chronic disease (mostly psychiatric disorders) on the day of the crash (OR=1.67 [1.22-2.30]). Among them, the risk was even higher in drivers with highest exposure levels (OR=2.60 [1.23-5.50]). There was no impact of sedating H1 antihistamine treatment initiation on the risk of crash.
Even if it is difficult to disentangle the part of the increased risk that would be causally related to hydroxyzine and the part related to behaviours of patients with a heavy psychiatric disorder, our study raises the alarm on the crash risk linked to hydroxyzine utilization in countries in which the anxiolytic indication is widespread.
H1抗组胺药在穿越血脑屏障的能力上存在差异。由此产生的镇静作用在治疗中可能是有益的,但也可能构成驾驶危险。本研究的目的是评估具有镇静作用的H1抗组胺药对道路交通事故风险的影响,特别关注在法国也被用作抗焦虑药的羟嗪。
该研究包括从三个法国全国性数据库中提取和匹配数据:国家医疗保险数据库、警方报告以及警方全国性伤害事故数据库。研究中纳入了所有具有镇静作用的H1抗组胺药,包括羟嗪。进行了病例对照分析,其中将负有责任的司机作为病例,无责任的司机作为对照。还进行了病例交叉分析,比较同一受试者在事故发生前即刻的暴露情况与更早时期的暴露情况。
在2005年7月至2011年12月期间的提取和匹配程序导致纳入了142,771名涉及道路交通事故受伤的司机。责任研究发现,在事故发生当天登记患有长期慢性病(主要是精神疾病)的羟嗪使用者中,对道路交通事故负有责任的风险增加(OR = 1.67 [1.22 - 2.30])。其中,暴露水平最高的司机风险更高(OR = 2.60 [1.23 - 5.50])。开始使用具有镇静作用的H1抗组胺药治疗对事故风险没有影响。
即使难以区分增加的风险中与羟嗪有因果关系的部分和与重度精神疾病患者行为相关的部分,我们的研究仍对在抗焦虑适应症广泛的国家中与使用羟嗪相关的事故风险发出了警报。